Form 4: Revolution Medicines CFO Jack Anders Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Jack Anders, CFO of Revolution Medicines, sold 2,244 shares of common stock on September 16, 2024, to cover tax obligations related to vesting restricted stock units.
Summary
- On September 16, 2024, Jack Anders, the Chief Financial Officer of Revolution Medicines, sold 2,244 shares of the company's common stock.
- The sale was executed at a price of $44.1853 per share.
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023, to cover tax withholding obligations upon the vesting of restricted stock units (RSUs).
- Following the transaction, Anders directly owns 98,932 shares of Revolution Medicines, which includes 50,000 RSUs.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock sale by an executive for tax purposes. It doesn't contain information that would significantly sway investor sentiment positively or negatively.
Industry Context
Sales by company insiders are a common occurrence, often related to tax obligations or diversification strategies. The use of a pre-arranged Rule 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| May 31, 2023 | Date of adoption of Rule 10b5-1 trading plan. |
| July 15, 2023 | Date after which the Rule 10b5-1 trading plan was active. |
| September 16, 2024 | Date of the stock sale transaction. |
| September 18, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.